Nature

‘Biotech Barbie’ says the time has come to consider CRISPR babies. Do scientists agree?

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
BioSpace

FDA Eyes Accelerated Reviews for Gene Editing Therapies

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
Nature

Personalized gene editing helped one baby: can it be rolled out widely?

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

FDA clears way for faster personalized gene editing therapy

Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...

CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation

CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...

Sharper gene scissors for the biotechnology toolbox

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
STATOpinion

For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...
CNA

Gene therapy could become mainstream in Singapore by 2030s, but ethical concerns remain

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
STAT

Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.
BioSpace

Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

A Look at CRISPR Therapeutics’s Valuation Following New CTX460 Gene Editing Breakthrough Data

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...